183 related articles for article (PubMed ID: 23333798)
1. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target.
Yang Y; Mallampati S; Sun B; Zhang J; Kim SB; Lee JS; Gong Y; Cai Z; Sun X
Cancer Lett; 2013 Jun; 333(1):9-17. PubMed ID: 23333798
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.
Iwasa M; Miura Y; Fujishiro A; Fujii S; Sugino N; Yoshioka S; Yokota A; Hishita T; Hirai H; Andoh A; Ichinohe T; Maekawa T
Int J Hematol; 2017 May; 105(5):587-597. PubMed ID: 28044259
[TBL] [Abstract][Full Text] [Related]
3. Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia.
Park CS; Yoshihara H; Gao Q; Qu C; Iacobucci I; Ghate PS; Connelly JP; Pruett-Miller SM; Wagner B; Robinson CG; Mishra A; Peng J; Yang L; Rankovic Z; Finkelstein D; Luger S; Litzow M; Paietta EM; Hebbar N; Velasquez MP; Mullighan CG
Cell Rep; 2023 Jul; 42(7):112804. PubMed ID: 37453060
[TBL] [Abstract][Full Text] [Related]
4. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
[TBL] [Abstract][Full Text] [Related]
5. BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL.
Zhang H; Zhang R; Zheng X; Sun M; Fan J; Fang C; Tian X; Zheng H
Cancer Sci; 2021 Mar; 112(3):1235-1250. PubMed ID: 33393145
[TBL] [Abstract][Full Text] [Related]
6. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
[TBL] [Abstract][Full Text] [Related]
7. Lithium stimulates human bone marrow derived mesenchymal stem cell proliferation through GSK-3β-dependent β-catenin/Wnt pathway activation.
Zhu Z; Yin J; Guan J; Hu B; Niu X; Jin D; Wang Y; Zhang C
FEBS J; 2014 Dec; 281(23):5371-89. PubMed ID: 25265417
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow mesenchymal stromal cells affect the cell cycle arrest effect of genotoxic agents on acute lymphocytic leukemia cells via p21 down-regulation.
Zhang Y; Hu K; Hu Y; Liu L; Wang B; Huang H
Ann Hematol; 2014 Sep; 93(9):1499-508. PubMed ID: 24705889
[TBL] [Abstract][Full Text] [Related]
9. [Effects of bone marrow stromal cells on the chemotherapeutic sensitivity of acute lymphoblastic leukemia cells].
Wang Y; Han ZX; Zhang JC
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):885-890. PubMed ID: 29262503
[No Abstract] [Full Text] [Related]
10. Overcoming Microenvironment-Mediated Chemoprotection through Stromal Galectin-3 Inhibition in Acute Lymphoblastic Leukemia.
Tarighat SS; Fei F; Joo EJ; Abdel-Azim H; Yang L; Geng H; Bum-Erdene K; Grice ID; von Itzstein M; Blanchard H; Heisterkamp N
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830047
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Wnt/β-catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury.
Wang C; Zhu H; Sun Z; Xiang Z; Ge Y; Ni C; Luo Z; Qian W; Han X
Am J Physiol Cell Physiol; 2014 Aug; 307(3):C234-44. PubMed ID: 24898581
[TBL] [Abstract][Full Text] [Related]
12. A novel Sprouty4-ERK1/2-Wnt/β-catenin regulatory loop in marrow stromal progenitor cells controls osteogenic and adipogenic differentiation.
Tian L; Xiao H; Li M; Wu X; Xie Y; Zhou J; Zhang X; Wang B
Metabolism; 2020 Apr; 105():154189. PubMed ID: 32105664
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.
Hu K; Gu Y; Lou L; Liu L; Hu Y; Wang B; Luo Y; Shi J; Yu X; Huang H
J Hematol Oncol; 2015 Jan; 8():1. PubMed ID: 25622682
[TBL] [Abstract][Full Text] [Related]
14. Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
Cheng L; Zeng S; Yan D; Tu L; Yang Y; Wang X; Zheng X
Leuk Res; 2021 Oct; 109():106649. PubMed ID: 34271301
[TBL] [Abstract][Full Text] [Related]
15. Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.
Wang L; O'Leary H; Fortney J; Gibson LF
Blood; 2007 Nov; 110(9):3334-44. PubMed ID: 17638851
[TBL] [Abstract][Full Text] [Related]
16. Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Shao N; Zou J; Li J; Chen F; Dai J; Qu X; Sun X; Ma D; Ji C
Leuk Lymphoma; 2012 Sep; 53(9):1769-78. PubMed ID: 22303878
[TBL] [Abstract][Full Text] [Related]
17. Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4.
Yu K; Yin Y; Ma D; Lu T; Wei D; Xiong J; Zhou Z; Zhang T; Zhang S; Fang Q; Wang J
Int Immunopharmacol; 2020 Mar; 80():106008. PubMed ID: 31978797
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
19. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
Burt R; Dey A; Aref S; Aguiar M; Akarca A; Bailey K; Day W; Hooper S; Kirkwood A; Kirschner K; Lee SW; Lo Celso C; Manji J; Mansour MR; Marafioti T; Mitchell RJ; Muirhead RC; Cheuk Yan Ng K; Pospori C; Puccio I; Zuborne-Alapi K; Sahai E; Fielding AK
Blood; 2019 Oct; 134(17):1415-1429. PubMed ID: 31501154
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
